Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution
- 31 December 2005
- journal article
- research article
- Published by Elsevier BV in Journal of Vascular Surgery
- Vol. 42 (6), 1183-1189
- https://doi.org/10.1016/j.jvs.2005.07.017
Abstract
ObjectivesEnhancing thrombus resolution may reduce the long-term complications of venous thrombosis. The aim of this study was to examine whether a sustained release of vascular endothelial growth factor (VEGF) would further improve thrombus recanalization.MethodsInferior caval vein thrombosis was induced in a cohort of 21 male Wistar rats. A plasmid encoding the human VEGF gene (phVEGF) was injected directly into thrombus (30 to 50 μg) and the muscle adjacent to the inferior vena cava (300 to 400 μg). A plasmid containing the gene encoding β-galactosidase (pCMVβ) was injected into the same sites of a separate cohort of rats to act as a control. Tissues were harvested after 1 and 2 weeks, and β-galactosidase activity was measured to estimate transfection efficiency. Muscle and serum VEGF were measured by enzyme-inked immunosorbent assay. Thrombus size, recanalization, and organization were determined by computer-assisted image analysis.ResultsThe efficiency of control plasmid transfection into muscle was about 1%. No serum hVEGF was detected in phVEGF- or pCMVβ-treated animals. Significantly raised levels of hVEGF (P < .01) were detected in the muscle injected with phVEGF after 2 weeks compared with control muscle. There was a significant reduction in thrombus size of 23% (P < .05) and 48% (P < .001) in phVEGF-treated animals compared with pCMVβ-treated controls after 1 and 2 weeks, respectively. Thrombus recanalization was a significantly greater in the phVEGF-treated group after 2 weeks (mean 19% ± 2% [SEM]) compared with controls (mean 13% ± 2%, P < .01). There were no differences in the thrombus organization score.ConclusionVEGF gene therapy of venous thrombus resulted in smaller thrombi with greater recanalization. Angiogenic gene therapy may form the basis of a novel treatment that may improve the resolution of venous thrombi.Clinical RelevanceDeep vein thrombosis may lead to residual venous obstruction or reflux and result in post-thrombotic complications that are debilitating and have a substantial socioeconomic impact. Enhancing the resolution of venous thrombi may reduce post thrombotic complicationsKeywords
This publication has 34 references indexed in Scilit:
- Recruitment of Labelled Monocytes by Experimental Venous ThrombiThrombosis and Haemostasis, 2001
- The Epidemiology of Venous Thromboembolism in the CommunityThrombosis and Haemostasis, 2001
- Determinants of chronic venous disease after acute deep venous thrombosisJournal of Vascular Surgery, 1998
- Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancementJournal of Vascular Surgery, 1997
- On the Relationship between Changes in the Deep Veins Evaluated by Duplex Sonography and the Postthrombotic Syndrome 12 Years after Deep Vein ThrombosisThrombosis and Haemostasis, 1997
- Laboratory assays and duplex scanning outcomes after symptomatic deep vein thrombosis: Preliminary resultsJournal of Vascular Surgery, 1996
- Deep venous insufficiency: The relationship between lysis and subsequent refluxJournal of Vascular Surgery, 1993
- A simple ultrasound approach for detection of recurrent proximal-vein thrombosis.Circulation, 1993
- Clinical Utility of Real-Time Compression Ultrasonography for Diagnostic Management of Patients with Recurrent Venous ThrombosisActa Radiologica, 1992
- A Population-Based Perspective of the Hospital Incidence and Case-Fatality Rates of Deep Vein Thrombosis and Pulmonary EmbolismArchives of Internal Medicine, 1991